Elsevier

Vaccine

Volume 25, Issue 3, 5 January 2007, Pages 458-465
Vaccine

Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

https://doi.org/10.1016/j.vaccine.2006.08.005Get rights and content

Abstract

Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

Introduction

In the Lazio region, Streptococcus pneumoniae is the main cause of meningitis in people of all ages. In 1998, the overall incidence was 1.1 per 100,000, which increases with age: in people 65 years of age or older the incidence rate was 1.3-times higher [1]. Information about other forms of invasive pneumococcal disease is not readily available: between 1997 and 1999 the annual incidence of community-acquired pneumonia-related hospitalisations was 480 per 100,000 people 65+, but the percentage of these inpatient episodes caused by S. pneumoniae and bacteraemia is not known with certainty [2].

Although the first 14-valent pneumococcal polysaccharide vaccine was marketed in 1978, and since 1983 a 23-valent vaccine has been available in developed countries, their efficacy in reducing morbidity and mortality among elderly people has not yet been proved [3]. The most favourable, although not definitive, results are found in preventing the invasive form of the disease, although the definition of invasive changes from study to study. Nevertheless, some governmental agencies and scientific societies recommend vaccinating people over 64 years of age, and some countries in fact have already begun vaccination campaigns [4]. Although the pneumococcal vaccine is not universally recommended for the elderly in Italy, several experimental vaccination campaigns have been conducted.

Most of the recent economic evaluations assume that only the invasive form of the disease can be prevented [5], [6], [7], [8], or they report separate estimates from alternative hypotheses: (i) protection against pneumococcal pneumonia and bacteraemic illness, or (ii) protection against bacteraemia only [9]. The efficacy of the pneumococcal vaccine is still the main source of uncertainty regarding its use [10]. Moreover, due to waning immunity, revaccination of elderly people after 5 years also may be required.

The objective of the present study was to estimate the cost-effectiveness of a hypothetical vaccination campaign among 65+ year olds in the general population in the Lazio region (Italy). Cost-effectiveness was expressed as net healthcare costs per invasive pneumococcal disease (IPD) episode averted and life-year gained (LYG).

Section snippets

Model

The model simulates the healthcare costs and health benefits of carrying out a pneumococcal vaccine program for people over 64 years old in the Lazio region. A cohort of elderly people, identified from official regional demographic statistics as of January 1, 2002, was followed over 5 years. Epidemiological parameters included incidence and case fatality rates of bacteraemic pneumococcal pneumonia and pneumococcal meningitis. Since randomised controlled trials and meta-analyses have not yet

Results

Baseline epidemiological parameters estimated from the Lazio region HIS data are reported in Table 1. Pneumococcal pneumonia incidence was corrected for underreporting. Since no pneumococcal meningitis episodes were recorded among people over 84 years of age between 2001 and 2003, incidence and case fatality in this age group were extrapolated from data on people less than 85 years of age. The estimated overall incidence of bacteraemic pneumococcal pneumonia and meningitis among the elderly

Limits and methodological remarks

Since the perspective of the economic evaluation was that of the health care provider, we included only direct medical costs. That is, we disregarded indirect costs from losses in patient productivity, which consist mostly of missed work, since the target population is over 64 years of age, and the additional costs of professional caregivers. The inclusion of direct costs for care-giving and indirect costs related to patient and caregiver productivity losses would give cost-effectiveness

Acknowledgements

The authors wish to thank Margaret Becker for the English editing, and the personnel at the Communicable Disease Unit and the Hospital Information System Unit of the Public Health Agency of the Lazio region, in particular Fabrizio Perrella, Maria Paola Guerra, Eliana Ferroni, Laura Alecci, Paolo Papini, Valeria Tancioni, Riccardo Salvatori.

References (39)

  • A. Melegaro et al.

    The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales

    Eur J Epidemiol

    (2004)
  • P. Mangtani et al.

    An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting

    Int J Epidemiol Adv Access

    (2005)
  • A.S. Artz et al.

    Pneumococcal vaccination and revaccination of older adults

    Clin Microbiol Rev

    (2003)
  • T.J. Marrie et al.

    Canadian community-acquired pneumonia investigators. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology—results from a Canadian multicentre study

    Can Respir J

    (2003)
  • M. Kalin et al.

    Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries

    J Infect Dis

    (2000)
  • A. Faustini et al.

    Estimating incidence of bacterial meningitis with capture-recapture method, Lazio Region

    Italy Eur J Epidemiol

    (2000)
  • M.P. Carrieri et al.

    Evaluation of the SIMI system, an experimental computerised network for the surveillance of communicable diseases in Italy

    Eur J Epidemiol

    (2000)
  • M.G. Pompa

    Surveillance of invasive diseases

    Ann Ig

    (2002)
  • A. Faustini et al.

    Role of laboratories in population-based surveillance of invasive diseases in Lazio, Italy, 1998–2000

    Eur J Clin Microbiol Infect Dis

    (2002)
  • Cited by (0)

    View full text